KALY Kali Inc.

KALY – Kali-Extracts Continues Cannabinoid Testing For CBD Extraction Contract Worth Anticipated $5 Million

KALY – Kali-Extracts Continues Cannabinoid Testing For CBD Extraction Contract Worth Anticipated $5 Million

DALLAS, Sept. 13, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced its continued cannabinoid testing on hemp flowers from its consigned hemp field in New York.  KALY has entered into a contract to extract CBD from a hemp crop managed by a licensed hemp grower in the State of New York.  The contract is anticipated to generate as much as $5 million in revenue for KALY.  The company is conducting regular periodic testing on hemp flowers from the consigned crop in New York.  The plants are approaching harvesting maturity and the purpose of the ongoing tests are to time the optimal harvest time to yield the highest CBD quality and content.  Current estimates expect harvesting to begin soon.  Ongoing test results may enable KALY to secure pre-harvest contracts on CBD.  The company has already received inquiries validating the potential of pre-harvest contracts.

KALY Analyst Coverage Speculating $0.05 PPS

The company recently announced a new analyst report from Goldman Small Cap Research covering the KALY’s recent biopharmaceutical cannabis extract business development updates.  The report can be found in its entirety on Goldman’s website .  The report speculates a potential KALY price per share of $0.05.

To view the full report visit:

To learn more about the company visit

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.

CONTACT:

Frederick Ferri



(214) 210-0459

EN
13/09/2019

Underlying

KALYKali Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kali Inc.

 PRESS RELEASE
Free
KALY KALI INC.

CORRECTION FROM SOURCE: KALY Exits Cannabis Business With Shareholder ...

This document corrects and replaces the press release that was issued by Kali Inc. (OTC Pink: KALY) (“KALY”) today July 16, 2020 at 11:24 am ET. The release below replaces the entirety of the previous release, as the incorrect release was sent.The corrected press release follows in full below:Dallas, Texas--(Newsfile Corp. - July 16, 2020) - Kali, Inc. (OTC Pink: KALY) ("KALY") today announced a deal in the works to sell its cannabis execration subsidiary, NCM Biotech, to PAO Group, Inc. (OTC Pink: PAOG) in exchange for common shares of PAOG that will in turn be issued to KALY shareholders in ...

July 16, 2020 1 EN
 PRESS RELEASE
Free
KALY KALI INC.

KALY Calls for Partners on Patented Technology and Potential COVID-19 ...

Dallas, Texas--(Newsfile Corp. - July 16, 2020) - Kali-Extracts, Inc. (OTC Pink: KALY) (Kali, Inc. dba/Kali-Extracts, Inc.) ("KALY") today issued a call for potential partners that could contribute to the acceleration of evaluating and developing KALY's proprietary CBD formulation developed for the treatment of symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. Researchers believe the CBD formulation could be effective in the treatment of symptoms resulting from COVID-19.The formulation for the treatment of symptoms associated with C...

July 16, 2020 1 EN
 PRESS RELEASE
Free
KALY KALI INC.

KALY Previews Investment Commitment Into Its Cannabis Biopharmaceutica...

Dallas, Texas--(Newsfile Corp. - February 3, 2020) - Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (OTC Pink: KALY) ("KALY"), today previewed a Letter of Intent (LOI) executed with a third-party investor. The LOI details are anticipated to be released tomorrow. Management indicates the two-stage investment is of substantial magnitude and can meaningfully advance the company's ongoing development of its cannabis biopharmaceutical technology. KALY has a U.S. Patented Cannabis Extraction Process it uses to produce proprietary formulations for the treatment of various medical conditi...

February 3, 2020 1 EN
 PRESS RELEASE
Free
KALY KALI INC.

KALY Patented Cannabis Biotech $50 Million Valuation Supported By Anal...

Dallas, Texas--(Newsfile Corp. - January 31, 2020) - Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (OTC Pink: KALY) ("KALY") today pointed to a on the legal marijuana market projecting the legal marijuana market to reach over $66 Billion in value by 2025 to support a recent $50 Million valuation of KALY's cannabis biotechnology. KALY has U.S. Patented Cannabis Extraction Process it uses to produce proprietary formulations for the treatment of various medical conditions. Grand View Research indicates the growing adoption of cannabis as a pharmaceutical is a substantial driver be...

January 31, 2020 1 EN
 PRESS RELEASE
Free
KALY KALI INC.

KALY- Kali-Extracts Proprietary CBD Extract Could Offer Coronavirus Re...

Dallas, Texas--(Newsfile Corp. - January 29, 2020) - Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (OTC Pink: KALY) ("KALY") today confirmed efforts to evaluate its proprietary CBD extract formulation as a treatment for coronavirus symptoms. KALY's proprietary CBD formulation has been developed for the treatment of symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the company's U.S. Patented...

January 29, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch